<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150175</url>
  </required_header>
  <id_info>
    <org_study_id>HKCTR-763</org_study_id>
    <secondary_id>END-HF Version 1:17-5-08</secondary_id>
    <nct_id>NCT01150175</nct_id>
  </id_info>
  <brief_title>Direct Endomyocardial Injection of Autologous Bone Marrow Cells to Treat Ischaemic Heart Failure</brief_title>
  <acronym>END-HF</acronym>
  <official_title>Double-blind Placebo Controlled Trial on Direct Endomyocardial Injection of Autologous Bone Marrow Cells for Enhancement of Neovascularization in Patients With Ischaemic Heart Failure (END-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether direct endomyocardial injection of&#xD;
      autologous bone marrow cells is effective for enhancement of neovascularisation in patients&#xD;
      with ischaemic heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery disease (CAD) remains to be one of the leading causes of mortality and&#xD;
      morbidity worldwide. Despite the optimal use of anti-anginal medications and coronary&#xD;
      revascularization, a large number of patients with CAD suffer from severe symptoms with&#xD;
      disabling angina and heart failure (HF). Experimental and pilot clinical studies provided&#xD;
      evidence of the safety and potential efficacy of a strategy of intramyocardial&#xD;
      transplantation of autologous bone marrow (BM) cells for neovascularisation of chronically&#xD;
      ischemic myocardium. Nevertheless, the possible potent placebo effect on symptoms observed in&#xD;
      these pilot studies highlights the need for a randomized, placebo-controlled group to prove&#xD;
      the clinical efficacy of cell based angiogenic therapy for treatment of severe CAD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI ejection fraction</measure>
    <time_frame>MRI ejection fraction changed from baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in exercise duration and MVO2 using standardized treadmill testing(modified Bruce protocol) from baseline to 6 months</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Autologous bone marrow cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endomyocardial Injection of Autologous Bone Marrow Cells</intervention_name>
    <description>Endomyocardial Injection of Autologous Bone Marrow Cells</description>
    <arm_group_label>Autologous bone marrow cells</arm_group_label>
    <other_name>END-HF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endomyocardial Injection of Plasma</intervention_name>
    <description>Endomyocardial Injection of Plasma</description>
    <arm_group_label>Plasma</arm_group_label>
    <other_name>END-HF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years old&#xD;
&#xD;
          -  Canadian cardiovascular (CV) Class II-IV angina and/or NYHA class II-III HF symptoms&#xD;
&#xD;
          -  Received stable and &quot;best&quot; cardiac medical therapy including long-acting nitrates,&#xD;
             beta-blocker, and angiotensin-converting enzyme inhibitors without control of&#xD;
             symptoms.&#xD;
&#xD;
          -  Not suitable for conventional revascularization by their referring cardiologist.&#xD;
&#xD;
          -  LVEF &lt;40% by echocardiography.&#xD;
&#xD;
          -  Recent coronary angiogram (within the last 6 months) to document the coronary anatomy&#xD;
             and insure the presence of CAD that is not amenable to standard revascularization&#xD;
             procedures.&#xD;
&#xD;
          -  creatinine less than 250mmol/L, normal liver function, and normal blood count: WBC,&#xD;
             granulocytes; platelet count, Hb.&#xD;
&#xD;
          -  Reversible perfusion defect on single photon emission computed tomography (SPECT)&#xD;
&#xD;
          -  Able to walk on treadmill&#xD;
&#xD;
          -  Hemodynamically stable&#xD;
&#xD;
          -  Subject is willing to comply with specified follow-up evaluations.&#xD;
&#xD;
          -  All patients give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  History of syncope or major ventricular arrhythmias such as sustained ventricular&#xD;
             tachycardia or ventricular fibrillation&#xD;
&#xD;
          -  Severe valve disease&#xD;
&#xD;
          -  Aortic or mitral valve prosthesis&#xD;
&#xD;
          -  History of cancer in last 5 years&#xD;
&#xD;
          -  Acute or chronic active sepsis, including HIV positive; hepatitis B or C positive&#xD;
&#xD;
          -  Left ventricular wall thickness less than 8 mm in the target territory&#xD;
&#xD;
          -  Left ventricular thrombus and/or spontaneous echo-contrast in the LV detected by&#xD;
             echocardiography or LV aneurysm&#xD;
&#xD;
          -  Severe aorto-femoral-iliac disease&#xD;
&#xD;
          -  Recent heart attack within the last 30 days&#xD;
&#xD;
          -  Hypertrophic or restrictive cardiomyopathy&#xD;
&#xD;
          -  Severe co-morbidity associated with a reduction in life expectancy of less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prof. HF Tse</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teguh Santoso, PhD</last_name>
      <phone>31930371</phone>
      <email>tsantoso@cbn.net.id</email>
    </contact>
    <contact_backup>
      <last_name>Thambar Sukumaran, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>David Siu, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <last_update_submitted>June 23, 2010</last_update_submitted>
  <last_update_submitted_qc>June 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. HF TSE</name_title>
    <organization>The University of Hong Kong</organization>
  </responsible_party>
  <keyword>END-HF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

